Table 1.
Histologic classification presented by a multicenter case–control study on patients with IgAN in Japan
| Histological grade | % glomeruli with pathological variables** predicting progression to ESRD | Acute lesion only | Acute and chronic lesion | Chronic lesion only |
|---|---|---|---|---|
| A. Hitological grade | ||||
| H-Grade I | 0–24.9 % | A | A/C | C |
| H-Grade II | 25–49.9 % | A | A/C | C |
| H-Grade III | 50–74.9 % | A | A/C | C |
| H-Grade IV | >75 % | A | A/C | C |
| Clinical grade | Proteinuria (g/day) | EGFR (ml/min/1.73 m2) | ||
|---|---|---|---|---|
| B. Clinical grade | ||||
| C-Grade I | <0.5 | – | ||
| C-Grade II | 0.5≤ | 60≤ | ||
| C-Grade III | <60 | |||
| Clinical grade | Histological grade | |||
|---|---|---|---|---|
| H-Grade I | H-Grade II | H-Grade III + IV | ||
| C. Grading system for predicting progression to ESRD | ||||
| C-Grade I | Low | Moderate | High | |
| C-Grade II | Moderate | Moderate | High | |
| C-Grade III | High | High | Super high | |
**Acute lesion (A): cellular crescent, tuft necrosis, fibrocellular crescent
Chronic lesion (C): global sclerosis, segmental sclerosis, fibrous crescent
Low risk group: *1 of 72 (1.4 %) of IgAN patients developed to ESRD in 18.6 years after RBx
Moderate risk group: *13 of 115 (11.3 %) of IgAN patients developed to ESRD in 11.5 (3.7-19.3) years after RBx
High risk group: *12 of 49 (24.5 %) of IgAN patients developed to ESRD in 8.9 (2.8–19.6) years after RBx
Super high risk group: *22 of 34 (64.7 %) of IgAN patients developed to ESRD in 5.1 (0.7–13.1) years after RBx
* The data from retrospective multicenter case–control study on IgAN (n = 287)